
Pharmaceuticals
an Open Access Journal by MDPI

Impact Factor 5.7
CiteScore 9.0
Indexed in PubMed

Section
Natural Products



mdpi.com/
journal/
pharmaceuticals

MDPI

Section Information

This section covers the wide range of substances extracted from natural sources such as terrestrial plants and marine organisms as well as their synthetic analogs. Chemical molecules isolated from natural sources are clearly inside the scope of Pharmaceuticals. In studies of complex mixtures of natural products, the characterization of chemicals using analytical methodologies, such as HPLC, MS, LC–MS, HPLC–MS, and NMR, should be included. In addition, only identification, chemistry, and analytical studies are not enough, in vitro or in vivo experiments are needed. It's expected that the cellular and molecular mechanisms of the natural compound or characterized extract to be analyzed in the paper.

Section Editor-in-Chief
Dr. Daniela De Vita

Editorial Office
pharmaceuticals@mdpi.com

MDPI
Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
mdpi.com

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

2025 Impact Factor: 5.7

(*Journal Citation Reports* - Clarivate, 2026)

Journal Rank

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Discounts on Article Processing Charges (APC)

If you belong to an institute that participates with the MDPI Institutional Open Access Program

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

Coverage by Leading Indexing Services

Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases

Rapid Publication

A first decision is provided to authors approximately 14.3 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2026)